Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

PLoS ONE - United States
doi 10.1371/journal.pone.0151846
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Efficacy and Safety of Icotinib as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Icotinib Is as Efficacious as Gefitinib for Brain Metastasis of EGFR Mutated Non-Small-Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy

Research in Oncology
2009English

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2018English

PCN37 Cost Comparison of Erlotinib Versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy